$BMSN /ENTB  Imen Vax  vaccines for  Canines

ImenVax ™ I

ImenVax ™ I, currently under development by the Company, is a therapeutic for canine cancer which utilizes the patient ’ s own tumor cells to induce the immune system to attack the remaining tumor cells. Tumor cells extracted from the patient are loaded into an implantable device where the tumor antigens are released to induce an anti-tumor response which kills the remaining tumors in the patient. The device is comprised of a chamber that includes a porous membrane wall that prevents the implanted cells from escaping the device but allows the tumor cells to survive and shed cancer antigens into the patient. The exposure of tumor specific antigens to the patient’s immune cells will stimulate anti-cancer immune responses.

ImenVax ™ II


The Company is also developing a version of ImenVax ™ called ImenVax ™ II utilizing cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses. It is believed by the Company that this controlled release of cytokines will act as an adjuvant to be combined with patient ’ s tumor cells (antigens) within an implantable membrane encapsulation device.


ImenVax ™ III


ImenVax ™ III is a canine cancer vaccine under development by the Company which does not require tumor processing. ImenVax ™ III treats existing tumors through stimulating immune responses to: a) kill tumor cells directly; b) indirectly kill tumor cells by cutting off the tumor blood supply; and c) block the ability of the tumor to suppress the immune system. ImenVax ™ III ’ s primary mode of action is generated through trophoblasts derived from human placental tissue.